A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia | Zendy

Vokes Ee | Zendy; Rosemarie Mick | Zendy; NJ Vogelzang | Zendy; R Geiser | Zendy; F Douglas | Zendy

Open Access

A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia

Author(s) -

Vokes Ee,

Rosemarie Mick,

NJ Vogelzang,

R Geiser,

F Douglas

Publication year - 1990

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1990.429

Subject(s) - magnesium , medicine , cisplatin , pharmacology , hydrochloride , endocrinology , chemotherapy , chemistry , biochemistry , organic chemistry

Magnesium aspartate hydrochloride (MgAH) (Magnesiocard, Ciba-Geigy, Summit, NJ, USA) is a magnesium compound designed for oral administration in the treatment of magnesium deficiency. The intent of this randomised trial was to determine if MgAH is able to prevent and/or replenish the cisplatin-induced loss of body stores of magnesium

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research